Takeyama Hiroshi, Manome Yoshinobu
Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan.
Department of Molecular Cell Biology, Jikei University School of Medicine, Tokyo, Japan.
Cancer Diagn Progn. 2023 Jan 3;3(1):75-84. doi: 10.21873/cdp.10182. eCollection 2023 Jan-Feb.
BACKGROUND/AIM: Sialyl-fibronectin (S-FN), a type of glycoprotein like Sialyl Lewis and MAC1 thyroid cancer biomarkers, has been found to be expressed in thyroid cancer. In this study, we examined the usefulness of serum S-FN as a biomarker, as well as prognostic factor in various tumors including thyroid cancer.
Using the MoAb JT-95, an ELISA kit was created and S-FN levels in sera (blood S-FN) of a total of 182 cases were investigated. Analysis included 63 cases of thyroid cancer, 33 cases of thyroid benign tumors, 7 cases of parathyroid benign tumors, and 79 cases of breast cancer.
The incidence of blood S-FN-positive cases was 24 (38.0%) in 63 examined patients with thyroid cancer. Out of 40 examined benign neck tumor cases, 16/40 (40%) were S-FN-positive. Out of 79 examined breast cancer cases, 20/79 (25.3%) were S-FN-positive, with significant differences between thyroid and breast cancer cases (p=0.007). Regarding the association of blood S-FN expression and prognosis in thyroid cancer, there was a significant difference between 39 blood S-FN-negative cases and 15 recurrent or metastatic cases in terms of progression and pathological factors: tumor size, lymph node metastasis, extra-membrane infiltration, and clinical stage. All 63 assessed thyroid cancer cases also had a significant difference in these factors. There were no significant differences between these factors in the 24 blood S-FN-positive thyroid cancer cases. In cases of recurrent metastasis, intravascular cells were observed in all recurrent metastasis patients of both groups. Regarding staining of intravascular infiltrating cells, recurrent metastasis appeared at a higher rate in cases with S-FN-negative infiltrating cells.
S-FN presence in blood can be used as an indicator of good prognosis in thyroid cancer patients.
背景/目的：唾液酸化纤连蛋白（S-FN）是一种类似于唾液酸化路易斯和MAC1的糖蛋白甲状腺癌生物标志物，已发现其在甲状腺癌中表达。在本研究中，我们检测了血清S-FN作为包括甲状腺癌在内的各种肿瘤的生物标志物以及预后因素的实用性。
使用单克隆抗体JT-95创建了一种ELISA试剂盒，并对总共182例患者血清中的S-FN水平（血液S-FN）进行了研究。分析包括63例甲状腺癌、33例甲状腺良性肿瘤、7例甲状旁腺良性肿瘤和79例乳腺癌。
在63例接受检查的甲状腺癌患者中，血液S-FN阳性病例的发生率为24例（38.0%）。在40例接受检查的颈部良性肿瘤病例中，16/40（40%）为S-FN阳性。在79例接受检查的乳腺癌病例中，20/79（25.3%）为S-FN阳性，甲状腺癌和乳腺癌病例之间存在显著差异（p = 0.007）。关于血液S-FN表达与甲状腺癌预后的关联，39例血液S-FN阴性病例与15例复发或转移病例在进展和病理因素方面存在显著差异：肿瘤大小、淋巴结转移、膜外浸润和临床分期。所有63例评估的甲状腺癌病例在这些因素上也存在显著差异。在24例血液S-FN阳性的甲状腺癌病例中，这些因素之间没有显著差异。在复发转移病例中，两组所有复发转移患者的血管内细胞均被观察到。关于血管内浸润细胞的染色，S-FN阴性浸润细胞的病例中复发转移的发生率更高。
血液中S-FN的存在可作为甲状腺癌患者预后良好的指标。
